Efficacy News and Research

RSS

Understanding the roles of NOTCH signaling in cancer resistance

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have seen minimal improvement, largely due to therapeutic resistance.

27 Mar 2025

New peptide antibiotic stops bacteria by binding where no drug has before

Researchers discovered lariocidin, a lasso peptide antibiotic that kills multidrug-resistant bacteria by binding a novel ribosomal site.

27 Mar 2025

AI-powered therapy chatbot shows significant mental health benefits

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results published March 27 in the New England Journal of Medicine AI.

27 Mar 2025

Study explores how sex chromosomes and hormones influence immune responses

Women have a higher proportion of key immune cells between puberty and menopause, which may be linked to the sex hormone estrogen and explain why they are less susceptible to certain infectious diseases than men, according to a new study led by researchers at UCL.

27 Mar 2025

Novel insights into tumor microenvironment and gastric cancer therapy

A team of Singapore scientists has made a significant discovery in understanding stomach cancer, a disease that remains one of the deadliest cancers worldwide. By using advanced mapping technologies, they created a detailed "atlas" of stomach tumors, revealing hidden patterns in how cancer cells behave, evolve and interact with their environment. These insights could lead to more precise, targeted treatments that improve survival rates and reduce side effects.

27 Mar 2025

Study identifies PDGFRA as a potential target for pediatric high-grade gliomas

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis.

26 Mar 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

Novel drug nitisinone could help reduce malaria spread by killing mosquitoes

In the fight against malaria, controlling the mosquito population is crucial.

26 Mar 2025

Scientists uncover rare gene variants that help people live past 100

Researchers studying over 2,000 Ashkenazi Jewish centenarians uncovered two rare IGF-1 gene variants linked to exceptional longevity. These variants reduce IGF-1 receptor activity through either diminished receptor binding or lower circulating IGF-1 levels.

26 Mar 2025

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Flavonoids show promise in treating type 2 diabetes mellitus by targeting the enteroendocrine system and regulating key gut hormones. They enhance insulin sensitivity, reduce oxidative stress, and influence appetite, glucose uptake, and hormone secretion.

26 Mar 2025

Microneedles accelerate diabetic wound healing in preclinical models

Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by persistent inflammation, affecting more than six per cent of the global population.

26 Mar 2025

Report shows alarming measles resurgence in Europe and US

A recent report shows cases of measles across the World Health Organization's European Region, which includes the UK, are the highest they've been for more than 25 years. At the same time, large outbreaks of measles in the US have led to the first measles deaths there since 2015.

26 Mar 2025

Ochsner Health study highlights benefits of combination therapy for cardiovascular risks

Ochsner Health Medical Director for Cardiac Rehabilitation and Preventive Cardiology, Carl J. "Chip" Lavie, Jr., MD, recently co-authored a groundbreaking research study featured in the prestigious Mayo Clinic Proceedings highlighting the comparative efficacy of lipid-lowering therapies for reducing cardiovascular risks and led by Maciej Banach, MD,PhD from Poland and leader of the International Lipid Expert Panel ( ILEP).

25 Mar 2025

Women with premenstrual syndrome appear to find relief from symptoms with placebos

Women affected by premenstrual syndrome (PMS) appear to experience less intense and debilitating symptoms after taking placebo pills even when told they do not contain any active medication, suggests a study published in the open-access journal BMJ Evidence-Based Medicine.

25 Mar 2025

New trial aims to make rectal cancer more responsive to radiation

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, has opened a phase 1 trial seeking to one day transform rectal cancer from a mostly radiation-resistant disease to one that can be cured using radiation and chemotherapy.

25 Mar 2025

Scientists develop universal vaccine targeting multiple coronaviruses

Sugar coatings aren't only for candies; they also help viruses, like the ones that cause COVID-19, hide from their hosts' immune system.

25 Mar 2025

Mapping the brain network behind generalized epilepsy

Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women's Hospital and an instructor of neurology at Harvard Medical School, is the senior author of a paper published in Nature Communications, "A generalized epilepsy network derived from brain abnormalities and deep brain stimulation."

25 Mar 2025

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 14-15 May. Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this year's event focused on 'drugging the undruggable'.

25 Mar 2025

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.

25 Mar 2025

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

Hepatitis B is a liver infection cause by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer than six months are considered "chronic".

24 Mar 2025